ctDNA test for skin cancer patients
Part of Cancer, Skin clinical trials.
This trial studies a blood test (ctDNA) in people with a type of skin cancer called cutaneous squamous cell carcinoma. It aims to see if the test can help track the cancer and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with cutaneous squamous cell carcinoma (a type of skin cancer).
- You are planning to have surgery to remove the cancer, and your cancer has certain high-risk features (like large size or nerve invasion).
- Or, you have cancer that has spread to nearby lymph nodes and you are not getting chemotherapy or targeted therapy before surgery.
- Or, you have advanced skin cancer that cannot be removed by surgery, and you are receiving immunotherapy (medicines that help your immune system fight cancer).
- You are not currently receiving any other systemic cancer treatment (like chemotherapy or targeted therapy) outside of what is allowed in this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test to look for tiny bits of tumor DNA after treatment for head and neck cancer. It aims to see if this test can detect any remaining cancer cells early, so you and your doctor can make informed decisions.
This trial tests a device placed on skin cancer lesions to see which drugs might work best. It is for people with visible squamous cell carcinoma on the skin, including lesions that have come back after radiation.
This study looks at whether measuring a DNA fragment in the blood (called ctDNA) can help predict how well radiotherapy works for head and neck cancer. It may help doctors better tailor treatment for patients with stage III or IV disease.
This trial tests a personalized blood test that looks for tumor DNA to monitor cervical cancer and help guide treatment decisions. It is for people with advanced or returning cervical cancer who haven't started treatment yet.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
Hear when a new Cutaneous Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.